FDA — authorised 25 February 1974
- Application: NDA017395
- Marketing authorisation holder: HOSPIRA
- Local brand name: INTROPIN
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 DOPAMINE HYDROCHLORIDE in United States
FDA authorised DOPAMINE HYDROCHLORIDE on 25 February 1974
Marketing authorisations
FDA — authorised 19 May 1981
- Application: NDA018132
- Marketing authorisation holder: HOSPIRA
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 28 June 1983
- Application: NDA018656
- Marketing authorisation holder: TELIGENT
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 30 September 1983
- Application: NDA018826
- Marketing authorisation holder: HOSPIRA
- Status: supplemented
FDA — authorised 23 October 1985
- Application: ANDA070092
- Marketing authorisation holder: IGI LABS INC
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 23 October 1985
- Application: ANDA070091
- Marketing authorisation holder: IGI LABS INC
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 15 October 1986
- Application: NDA019099
- Marketing authorisation holder: B BRAUN
- Local brand name: DOPAMINE HYDROCHLORIDE AND DEXTROSE 5% IN PLASTIC CONTAINER
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 11 February 1987
- Application: ANDA070826
- Marketing authorisation holder: AM REGENT
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 11 February 1987
- Application: ANDA070799
- Marketing authorisation holder: AM REGENT
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 11 February 1987
- Application: ANDA070820
- Marketing authorisation holder: AM REGENT
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 27 March 1987
- Application: NDA019615
- Marketing authorisation holder: BAXTER HLTHCARE
- Local brand name: DOPAMINE HYDROCHLORIDE IN DEXTROSE 5% IN PLASTIC CONTAINER
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 23 October 1991
- Application: ANDA072999
- Marketing authorisation holder: TEVA PARENTERAL
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 23 October 1991
- Application: ANDA073000
- Marketing authorisation holder: TEVA PARENTERAL
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 30 August 1995
- Application: NDA020542
- Marketing authorisation holder: HOSPIRA
- Local brand name: DOPAMINE HYDROCHLORIDE IN DEXTROSE 5%
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 23 May 1996
- Application: ANDA074403
- Marketing authorisation holder: HOSPIRA
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 11 April 2018
- Application: ANDA207707
- Marketing authorisation holder: HIKMA INTL PHARMS
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA070657
- Marketing authorisation holder: ABBOTT
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA070656
- Marketing authorisation holder: ABBOTT
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA070093
- Marketing authorisation holder: IGI LABS INC
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA070094
- Marketing authorisation holder: IGI LABS INC
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA070013
- Marketing authorisation holder: ABRAXIS PHARM
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: NDA018138
- Marketing authorisation holder: WARNER CHILCOTT
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA070012
- Marketing authorisation holder: ABRAXIS PHARM
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA070558
- Marketing authorisation holder: WARNER CHILCOTT
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Status: approved
FDA
- Application: ANDA070011
- Marketing authorisation holder: SMITH AND NEPHEW
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA070364
- Marketing authorisation holder: ABRAXIS PHARM
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA070058
- Marketing authorisation holder: ABRAXIS PHARM
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA070059
- Marketing authorisation holder: ABRAXIS PHARM
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA070047
- Marketing authorisation holder: SMITH AND NEPHEW
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA070046
- Marketing authorisation holder: SMITH AND NEPHEW
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA070087
- Marketing authorisation holder: IGI LABS INC
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA070089
- Marketing authorisation holder: IGI LABS INC
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA070090
- Marketing authorisation holder: IGI LABS INC
- Local brand name: DOPAMINE HYDROCHLORIDE
- Indication: INJECTABLE — INJECTION
- Status: approved
DOPAMINE HYDROCHLORIDE in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is DOPAMINE HYDROCHLORIDE approved in United States?
Yes. FDA authorised it on 25 February 1974; FDA authorised it on 19 May 1981; FDA authorised it on 28 June 1983.
Who is the marketing authorisation holder for DOPAMINE HYDROCHLORIDE in United States?
HOSPIRA holds the US marketing authorisation.